Happify Health forms digital therapeutics alliance with Sanofi

18 September 2019 (Last Updated September 18th, 2019 11:32)

Happify Health, a provider of mental health technology and digital therapeutics, has partnered with pharmaceutical giant Sanofi to offer prescription digital therapeutics for improving the mental health of multiple sclerosis (MS) patients.

Happify Health forms digital therapeutics alliance with Sanofi
New digital therapeutic to help address mental health problems in multiple sclerosis patients. Credit: Yura Fresh on Unsplash.

Happify Health, a provider of mental health technology and digital therapeutics, has partnered with pharmaceutical giant Sanofi to offer prescription digital therapeutics for improving the mental health of multiple sclerosis (MS) patients.

As part of the alliance, Happify Health will create an MS-specific variant of its existing digital mental health platform, evaluating its safety and efficacy in the patient population.

The company’s existing platform showed effectiveness in mitigating anxiety and depression in a previous randomised, controlled study of the general population.

Use of the Happify solution at the recommended level led to a 25% reduction in both anxiety and depression symptoms. Further research revealed that more than 40% of the users are still using the platform after 12 months.

Following successful clinical validation of the digital therapeutic, Happify Health and Sanofi will seek clearance from the US Food and Drug Administration (FDA) for the solution as a medical device.

Happify Health co-founder and president Ofer Leidner said: “Our experience as a successful direct-to-consumer application with nearly four million users and our commercial relationships with some of the nation’s largest health plans and multinational employers, has allowed us to develop some highly differentiated capabilities.

“These capabilities, along with Sanofi’s demonstrated commitment to digital transformation, made for an ideal collaboration rooted in exploring innovative, safe and effective therapies aiming to improve the lives of individuals with MS.”

According to statistics, major depressive disorder is three times as prevalent in MS patients as the general population, while anxiety is estimated to be 20% more prevalent.

The company’s digital therapeutic is expected to help address these co-morbidities.

Sanofi digital medicine global head Bozidar Jovicevic said: “Until now, physicians treating MS, have not had evidence-based, digital tools to treat comorbidities in tandem with the primary condition.

“In collaboration with Happify Health, we now have the opportunity to develop an MS-specific digital therapeutic based on a platform that is not only poised to affect outcomes but is also proven to be engaging, a critical factor for improving overall patient health.”

The partnership may be extended to use Happify Health technology to improve patient outcomes.